Under one in 10 people that would benefit from obesity jabs including Wegovy have access to them, states the World Health Organization as it issues its inaugural advice on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for more widespread and fairer availability to this class of drugs.
Based on projections, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our new guidance acknowledges that excess weight is a long-term condition that can be managed with comprehensive and continuous treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are significant obstacles to widespread availability to the injections that can help people shift substantial body mass, explains the agency.
GLP-1 Therapy Supply Crisis
Despite the present most optimistic outlook, the production of these medications might only reach around 100 million people – fewer than 10% of eligible patients, per the WHO.
The advice urges countries and companies to increase availability, via measures such as voluntary licensing.
Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is scheduled to end in several countries in 2026.
The Way Obesity Drugs Work
GLP-1 drugs imitate a body's own hormone to delay gastric emptying, curb appetite and boost satiety so users eat less.
People commonly see weight reduction after several weeks of beginning the weekly injections.
Research points to patients may regain a significant portion after a year of halting the treatment, when their normal hunger resume.
Being above a healthy weight elevates your likelihood for contracting medical conditions, including diabetes, cardiovascular issues, brain attack, and specific cancers.
Excess weight affects people in all nations and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
